NCT00389051View on ClinicalTrials.gov

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 5, 2007

Study Completion Date

October 26, 2007

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

bendamustine hydrochloride

1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)

Trial Locations (4)

Unknown

Kanagawa

Kyoto

Nagoya

Tokyo

Sponsors
All Listed Sponsors
lead

SymBio Pharmaceuticals

INDUSTRY